Financial Data and Key Metrics Changes - Q1 2021 revenue increased by 11%, with a 17% gain when adjusted for foreign exchange effects [13] - Gross margin was 23.1%, lower than the previous year due to the fadeout of the Sanofi subsidy and lower milestone achievements [14] - Adjusted EBITDA for Q1 2021 was €21.1 million, aligning with expectations [17] - Net income amounted to €52.7 million, benefiting from a one-off effect related to the fair value adjustment of Exscientia shares [17] Business Line Data and Key Metrics Changes - Execute revenues increased to €137 million from €118 million in Q1 2020, driven by demand for integrated offerings [20] - Innovate Q1 revenues reached €28.2 million, a 21% increase year-over-year, reflecting higher demand for precision medicine [22] - The gross margin for Execute was 21.4%, down from 29.3% the previous year, primarily due to the absence of Sanofi payments [21] Market Data and Key Metrics Changes - The overall sales development was negatively impacted by the end of Sanofi Toulouse payments and adverse foreign exchange effects, with a currency effect of minus €6 million [24] - The company reported a strong organic growth of 26% in the base business, indicating solid revenue quality from sustainable repeat business [23] Company Strategy and Development Direction - The company introduced an updated business model called "Action Plan 2025," focusing on data-driven R&D and achieving leadership in data and science [6][7] - The strategy emphasizes building a co-owned pipeline and leveraging data for drug discovery, aiming to create significant value through innovation [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 2021 goals despite ongoing COVID-19 challenges, with a strong long-term outlook [5] - The company anticipates increased activity in its co-owned pipeline as clinical centers reopen, expecting positive momentum in the second half of the year [30] - The long-term plan includes expected group revenues between €560 million and €570 million and EBITDA between €105 million and €120 million for 2021 [41] Other Important Information - Total liquidity decreased to €460.6 million, primarily due to expected capital expenditures for growth projects [27] - The company is committed to ESG initiatives, integrating these topics into employee goals and organizational strategies [39][40] Q&A Session Questions and Answers Question: Details on the OxVax collaboration - The company views itself as an operational synergy-seeking investor in the OxVax project, leveraging its iPSC platform [45] Question: Clarification on the collaboration with BMS - The partnership with BMS focuses on exploiting protein degradation strategies, but specific details cannot be disclosed [46] Question: Update on EVT801 and expectations from Kazia Therapeutics - The clinical entry for EVT801 is expected by the end of 2021 or early 2022, with Kazia showing strong scientific insight [47] Question: Extrapolation of operating income for the year - The operating income is expected to remain stable, with slight increases in tax credits and SG&A as the organization grows [55] Question: Update on the beta cell project and monetization of data - The CureBeta initiative is progressing well, with discussions ongoing with pharma and venture partners for potential licensing or company formation [60] - The company is already monetizing data through partnerships, such as with Novo Nordisk, leveraging its NURTuRE database [61] Question: Update on iPSC candidates entering the clinic - The first iPSC-derived novel target is expected to enter the clinic in the second half of 2021, with positive progress reported [86]

H PECCAACUNGVERJIVIN Accelerating on the data- driven Autobahn to Cures 【】【】【【】【 Evotec SE, First quarter 2021 results, 11 May 2021 Cautionary statement regarding forward-looking statements Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate", "believe", "could", "estimate", "expect", "goa ...

| --- | --- | |-------------------------------------------------------------------------------------------|-------| | | | | | | | The data-driven R&D Autobahn to Cures Evotec SE, Full-year 2020 results, 25 March 2021 | | and and the see and a be a comment of the subseries of Forward looking statement | --- | |--------------------------------------------------------------------------------------------| | | | Information set forth in this presentation contains forward-looking statements, which | | involve a n ...

Evotec SE (OTCPK:EVOTF) Q4 2020 Earnings Conference Call March 25, 2021 9:00 AM ET Company Participants Werner Lanthaler - CEO Enno Spillner - CFO Cord Dohrmann - Chief Scientific Officer Craig Johnstone - COO Conference Call Participants Joseph Hedden - Rx Securities Limited Falko Friedrichs - Deutsche Bank Charles Weston - RBC Capital Markets Naresh Chouhan - Intrinsic Health Advisors Victoria English - MedNous Mohamad Vaseghi - Frankfurt Main Research Christian Ehmann - Warburg Research Operator Dear lad ...

Evotec SE (OTCPK:EVOTF) Q3 2020 Earnings Conference Call November 12, 2020 8:00 AM ET Company Participants Werner Lanthaler - CEO Enno Spillner - CFO Craig Johnstone - COO Cord Dohrmann - Chief Scientific Officer Conference Call Participants Igor Kim - Bankhaus Lampe Nick Nieland - Citigroup Charles Weston - RBC Capital Markets Bruno Bulic - Baader-Helvea Joseph Hedden - Rx Securities Limited Naresh Chouhan - Intrinsic Health Advisors Kieron Banerjee - goetzpartners securities Victoria English - Evernow Pub ...

Financial Performance (9M 2020) - Group revenues increased by 12% to €360.4 million compared to €321.4 million in 9M 2019 [11] - Like-for-like growth of the base business, adjusted for portfolio and FX effects, was up by 19% [11] - Adjusted Group EBITDA was €76.9 million, compared to €93.2 million in 9M 2019, but showed a strong upswing in Q3 [11] - Increased investment in unpartnered R&D expenses to €33.4 million, up from €25.7 million in 9M 2019 [11] - R&D expenses reached €46.1 million, a 12% increase from €41.3 million in 9M 2019 [17] Q3 2020 Highlights - Revenue growth was driven by strong performance in the base business, with improved revenues from milestones, upfronts, and licenses [21] - Revenues from contracts with customers reached €129.4 million in Q3 2020, compared to €114.3 million in Q3 2019 [21] Guidance 2020 - Total Group revenues are expected to range from €440 million to €480 million, based on constant 2019 exchange rates [11, 48] - Adjusted Group EBITDA is expected to be in the range of €100 million to €120 million [11, 48] - Unpartnered Group R&D expenses are projected to be approximately €45 million [11, 48] Strategic Investments and Partnerships - Mubadala Investment Company made a €200 million investment, translating into 5.6% of the total new number of 163.5 million Evotec shares [15]

U MECCABCHNEVCKJIDTO Evotec Partnered Drug Discovery and Development Evotec SE, Company Presentation, H.C. Wainwright 22nd Annual Global Investment Conference, 14 September 2020 Forward-looking statement Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this presentation. Such forward-looking statements are neither promises nor g ...

U PECEADCHNEVERJIUTS Evotec Partnered Drug Discovery and Development Evotec SE, Company Presentation, Morgan Stanley 18th Annual Global Healthcare Conference, 16 September 2020 Forward-looking statement Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this presentation. Such forward-looking statements are neither promises nor gu ...

Evotec SE (OTCPK:EVOTF) Q2 2020 Earnings Conference Call August 12, 2020 8:00 AM ET Company Participants Werner Lanthaler - Chief Executive Officer Enno Spillner - Chief Financial Officer Craig Johnstone - Chief Operating Officer Cord Dohrmann - Chief Scientific Officer Conference Call Participants Joseph Hedden - Rx Securities Igor Kim - Bankhaus Lampe Falko Friedrichs - Deutsche Bank AG Victoria English - Evernow Publishing Ltd Boobalan Pachaiyappan - H.C. Wainwright & Co., LLC Naresh Chouhan - Intron Hea ...

evotec #RESEARCHNEVERSTOPS "We are Autobahn" OM MERCIA PRODUCT PRECLINICAL ADRUG DISCOVERY DISCOVERY PLATFORM T CELL & GENE "3" Evotec SE, H1 2020 Interim Report, 12 August 2020 Forward-looking statement Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this presentation. Such forward-looking statements are neither promises nor g ...